Compare Revvity Inc (RVTY) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs S&P Global Inc — how do they compare? Revvity Inc trades at $116.01 (market cap $12.91B), while S&P Global Inc trades at $408.56 (market cap $120.48B). The key difference: S&P Global Inc is far larger — about 9.3× Revvity Inc's market cap, and S&P Global Inc pays the higher dividend (0.95%). Which is the better fit depends on your goals.
| RVTY | SPGI | |
|---|---|---|
Market Cap | $12.91B | $120.48B |
Sector | Technology | Financials |
52-Week High | $117.75 | $534.79 |
52-Week Low | $82.26 | $370.42 |
Enterprise Value | $15.23B | $131.97B |
Dividend Yield | 0.24% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
S&P Global (SPGI) trades at $409.55, down 0.34% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $4.83, beating estimates, with revenue growth accelerating to $15.34B in 2025. Analyst consensus remains strongly bullish with 85.7% buy ratings and a $523.20 price target, representing 28% upside potential from current levels.
SPGI presents a compelling investment case with robust profitability (30.5% net margin) and strategic AI partnerships, though technical indicators suggest near-term pressure. The key risk involves maintaining premium valuations (P/E 24.9) amid economic uncertainty, while institutional confidence remains high with aggressive buyback programs supporting shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
